Patient demographics and disease history
| Demographic parameter . | All patients (N = 210) . |
|---|---|
| Age (y), median (range) | 66.5 (25-86) |
| Race, white, n (%) | 185 (88.1) |
| Sex, male, n (%) | 132 (62.9) |
| ECOG score, 0/1/2, % | 28.1/65.2/6.7 |
| Number of prior systemic therapies, median (range) | 3.0 (0-11) |
| ≥3 prior systemic regimens, n (%) | 133 (63.3) |
| Current diagnosis at enrollment, n (%) | |
| iNHL | 31 (14.8) |
| FL | 24 (11.4) |
| iNHL (not otherwise specified) | 1 (0.5) |
| MZL | 2 (1.0) |
| WM/LPL | 4 (1.9) |
| CLL/SLL (RR) | 55 (26.2) |
| CLL | 50 (23.8) |
| SLL | 5 (2.4) |
| CLL (TN) | 18 (8.6) |
| T-cell NHL | 35 (16.7) |
| Cutaneous TCL | 19 (9.0) |
| Peripheral TCL | 16 (7.6) |
| Other diagnoses | 71 (33.8) |
| aNHL | 26 (12.4) |
| MCL | 10 (4.8) |
| AML | 6 (2.9) |
| MM | 3 (1.4) |
| HL | 3 (1.4) |
| Myelofibrosis | 5 (2.4) |
| MDS | 6 (2.9) |
| T-cell ALL | 5 (2.4) |
| B-cell ALL | 4 (1.9) |
| LGL | 3 (1.4) |
| Demographic parameter . | All patients (N = 210) . |
|---|---|
| Age (y), median (range) | 66.5 (25-86) |
| Race, white, n (%) | 185 (88.1) |
| Sex, male, n (%) | 132 (62.9) |
| ECOG score, 0/1/2, % | 28.1/65.2/6.7 |
| Number of prior systemic therapies, median (range) | 3.0 (0-11) |
| ≥3 prior systemic regimens, n (%) | 133 (63.3) |
| Current diagnosis at enrollment, n (%) | |
| iNHL | 31 (14.8) |
| FL | 24 (11.4) |
| iNHL (not otherwise specified) | 1 (0.5) |
| MZL | 2 (1.0) |
| WM/LPL | 4 (1.9) |
| CLL/SLL (RR) | 55 (26.2) |
| CLL | 50 (23.8) |
| SLL | 5 (2.4) |
| CLL (TN) | 18 (8.6) |
| T-cell NHL | 35 (16.7) |
| Cutaneous TCL | 19 (9.0) |
| Peripheral TCL | 16 (7.6) |
| Other diagnoses | 71 (33.8) |
| aNHL | 26 (12.4) |
| MCL | 10 (4.8) |
| AML | 6 (2.9) |
| MM | 3 (1.4) |
| HL | 3 (1.4) |
| Myelofibrosis | 5 (2.4) |
| MDS | 6 (2.9) |
| T-cell ALL | 5 (2.4) |
| B-cell ALL | 4 (1.9) |
| LGL | 3 (1.4) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; aNHL, aggressive non-Hodgkin lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; LGL, large granular lymphocytic leukemia; LPL, lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MZL, marginal zone lymphoma; WM, Waldenström macroglobulinemia.
Bold entries in patient column denote disease subtypes represented in the patient population.